SCHEMBL23706252

SCHEMBL23706252

NCc1cc(CCc2ccccc2)ccn1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 1/20 0.51
MAOA P21397 5/20 0.47
MAOB P27338 4/20 0.47
LOXL2 Q9Y4K0 6/20 0.45
CYP2A6 P11509 1/20 0.45
HTR2A P28223 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
TAAR1 Q96RJ0 1/20 0.45
KCNH2 Q12809 1/20 0.44
LOX P28300 2/20 0.44
HRH1 P35367 1/20 0.42
ABCB1 P08183 1/20 0.41
HTR1A P08908 1/20 0.41
DRD2 P14416 1/20 0.41
LOXL3 P58215 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11630184 0.85 CALM1 (0.46) NR3C2LOXL2TAAR1LOXHRH1
SCHEMBL16583871 0.82 LOXL2 (0.52) LOXL2CYP2A6HTR2ASMN1; SMN2TAAR1
SCHEMBL4107151 0.79 LOXL2 (0.61) LOXL2LOXLOXL3
SCHEMBL8989727 0.78 NOS3 (0.57) NR3C2MAOAMAOBLOXL2CYP2A6
SCHEMBL16502197 0.78 NR3C2 (0.51) NR3C2MAOAMAOBSMN1; SMN2KCNH2
Hydrochloric Acid SCHEMBL5013442 0.77 LOXL2 (0.59) LOXL2LOXLOXL3
SCHEMBL10651314 0.77 LOXL2 (0.46) LOXL2LOXHRH1LOXL3
SCHEMBL23705841 0.77 LOXL2 (0.53) MAOAMAOBLOXL2SMN1; SMN2KCNH2
SCHEMBL1931475 0.75 MAOB (0.53) MAOAMAOBSMN1; SMN2
SCHEMBL30931669 0.75 MAOB (0.53) MAOAMAOBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12441726-B2 Compounds and uses thereof FOGHORN THERAPEUTICS, INC. (US) 2025-10-14 US disclosed
CN-115297861-B Compounds and uses thereof 福宏治疗公司 2024-07-12 CN disclosed
US-20230145003-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-11 US disclosed
US-20230145003-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-11 US disclosed
EP-4096667-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2022-12-07 EP disclosed
CN-115297861-A Compound and use thereof 福宏治疗公司 2022-11-04 CN disclosed
WO-2021155320-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12441726-B2 Compounds and uses thereof VHL, CLN6, TFEB NR3C2 2125/4885MAOA 2223/4885MAOB 975/4885
US-20230145003-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB NR3C2 2125/4885MAOA 2223/4885MAOB 975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.